

# Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

## Spark Blue(TM) 550 anti-human CD14

RRID:AB\_2832724

Type: Antibody

---

### Proper Citation

BioLegend Cat# 367148, RRID:AB\_2832724

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2832724](http://antibodyregistry.org/AB_2832724)

**Proper Citation:** BioLegend Cat# 367148, RRID:AB\_2832724

**Target Antigen:** CD14

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Spark Blue(TM) 550 anti-human CD14

**Description:** This monoclonal targets CD14

**Target Organism:** human

**Clone ID:** Clone 63D3

**Antibody ID:** AB\_2832724

**Vendor:** BioLegend

**Catalog Number:** 367148

**Alternative Catalog Numbers:** 367147

**Record Creation Time:** 20231110T032404+0000

**Record Last Update:** 20260829T091754+0000

---

### Ratings and Alerts

No rating or validation information has been found for Spark Blue(TM) 550 anti-human CD14.

No alerts have been found for Spark Blue(TM) 550 anti-human CD14.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Marciello I, et al. (2025) Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry. *STAR protocols*, 6(2), 103775.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. *Cancer cell*.

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. *The Journal of experimental medicine*, 222(7).

de Homdedeu M, et al. (2023) Mycobacterium manresensis induces trained immunity in vitro. *iScience*, 26(6), 106873.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Szymula A, et al. (2023) Macrophages drive KSHV B cell latency. *Cell reports*, 42(7), 112767.

Haubner S, et al. (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. *Cancer cell*, 41(11), 1871.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. *Cell reports*, 38(2), 110235.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.

Mulder K, et al. (2021) Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. *Immunity*, 54(8), 1883.